Skip to main content
Funded Studies

Thomas S. Wessel, MD, PhD

Acting Chief Medical Officer at NurrOn Pharmaceuticals, Inc.

Location: Woburn, MA United States

Tom Wessel is a board-certified neurologist and has experience in all stages of CNS drug development. He started his career at Janssen (Johnson & Johnson) where he served as the medical director and NDA submission team leader for the FDA-approved drug RAZADYNE® (galantamine). Subsequently, he established the CNS clinical research group at Sepracor, where he supervised the late stage clinical studies and the NDA assembly for LUNESTA® (eszopiclone). He participated in the commercial launch and helped plan the phase 4 studies for LUNESTA® (eszopiclone) with academic clinical researchers which included successful clinical trials in major depression and other psychiatric disorders. He was the chief medical officer at Acorda Therapeutics where he worked on the NDA for AMPYRA® (dalfampridine) and made the safety presentation the FDA Advisory Committee for that product; he also served as CMO at Flex Pharma and Asceneuron as well as EVP of R&D for RelmadaTherapeutics.

Associated Grants

  • Development of a Nurr1 Activator as a Novel Therapeutic for Parkinson’s Disease


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.